The $275m round, the largest series B for three months, featured several pharmaceutical companies and is part of a thriving environment for gene therapy startups.

Aleks Engel, a Novo partner and Repair Impact Fund director, will work with the firm’s bioindustrial team to accelerate sustainability.

Take time, focus on quality and internal relationships, make an impact — these are the top resolutions investors have for 2023.

2022 saw a screeching turnaround in market sentiment. How well did corporate investors cope?

Corporate investors are backing a host of elder-care startups, from those seeking Parkinson's cures to apps aiding mental wellbeing.

A Japan-based university spinout is exploring a sound and touch treatment for dementia.

The cancer drug developer popped after an upsized offering, allowing Alexandria Venture Investments to exit and showing the IPO market is still breathing in the US.

The UK health insurer says it is a good time to launch a fund as the froth has come out of valuations and "sensible" money can go in.

NCSoft invested $15m in Mysten Labs to take the latter’s series B round to $300m while Porsche backed Xanadu’s $100m series C.

Suzano and Yara participated in Agrolend’s $145m latest round while Xencor contributed to Zenas BioPharma’s $118m series B.